Search results for "Randomized Controlled Trial"

showing 10 items of 2199 documents

Cost Effectiveness of Peginterferon ??-2a Plus Ribavirin versus Interferon ??-2b Plus Ribavirin as Initial Therapy for Treatment-Naive Chronic Hepati…

2004

Introduction: In adults with previously untreated chronic hepatitis C (CHC), the combination of peginterferon α-2a plus ribavirin produces a higher rate of sustained virological response (SVR) than interferon α-2b plus ribavirin, but it is still unproven whether this increase is cost effective. The objective of this study was to determine if the gain in SVR with peginterferon α-2a plus ribavirin is worth the incremental cost. Methods: We constructed a Markov model of disease progression in which cohorts of patients received peginterferon α-2a plus ribavirin or interferon α-2b plus ribavirin for 48 weeks (hepatitis C virus [HCV] genotype 1 and non-1 patients with fibrosis) or 24 weeks (genot…

medicine.medical_specialtyCirrhosisGenotypeCost effectivenessCost-Benefit AnalysisHepatitis C virusInterferon alpha-2medicine.disease_causeAntiviral AgentsSensitivity and SpecificityGastroenterologypeginterferon alpha2aPolyethylene Glycolschemistry.chemical_compoundchronic hepatitiInterferonInternal medicineRibavirinmedicineHumansRandomized Controlled Trials as Topicalpha2b interferonAntiviral AgentPharmacologybusiness.industryHealth PolicyRibavirinPublic Health Environmental and Occupational HealthInterferon-alphavirus diseasesHealth Care CostsHepatitis CHepatitis C Chronicmedicine.diseaseMarkov ChainsRecombinant Proteinsdigestive system diseasesModels EconomicTreatment OutcomechemistryImmunologyQuality of LifePeginterferon alfa-2bDrug Therapy CombinationbusinessPeginterferon alfa-2amedicine.drugPharmacoEconomics
researchProduct

Optimizing the treatment of chronic hepatitis due to hepatitis C virus genotypes 2 and 3: a review

2009

Recently several randomized trials involving exclusively HCV 2 and 3 patients have explored the possibility of reducing the duration of therapy with PEG IFNs and ribavirin to 12–16 weeks. Among these, the largest studies (ACCELERATE, NORTH-C and NORDynamIC) have failed to demonstrate, by intention-to-treat analysis, that short treatment is non-inferior to the standard duration of 24 weeks originated by phase 3 trials. Even though obtaining univocal conclusions from these studies are difficult to obtain due to some critical differences (trial design, genotypes 2/3 ratio, rate of cirrhosis at baseline, ribavirin dose, assays to detect HCV-RNA etc), all have proved that a rapid virological res…

medicine.medical_specialtyCirrhosisGenotypeHepatitis C virusHepacivirusInterferon alpha-2medicine.disease_causeAntiviral AgentsDrug Administration SchedulePolyethylene Glycolslaw.inventionchemistry.chemical_compoundPharmacotherapyRandomized controlled triallawInterferonInternal medicineRibavirinmedicineHumansHepatologybusiness.industryRibavirinInterferon-alphavirus diseasesHepatitis CHepatitis C Chronicmedicine.diseaseRecombinant Proteinsdigestive system diseaseschemistryImmunologyDrug Therapy CombinationViral hepatitisbusinessmedicine.drugLiver International
researchProduct

Enoxaparin Prevents Portal Vein Thrombosis and Liver Decompensation in Patients With Advanced Cirrhosis

2012

BACKGROUND & AIMS: We performed a randomized controlled trial to evaluate the safety and efficacy of enoxaparin, a low-molecular-weight heparin, in preventing portal vein thrombosis (PVT) in patients with advanced cirrhosis. METHODS: In a nonblinded, single-center study, 70 outpatients with cirrhosis (Child-Pugh classes B7-C10) with demonstrated patent portal veins and without hepatocellular carcinoma were assigned randomly to groups that were given enoxaparin (4000 IU/day, subcutaneously for 48 weeks; n = 34) or no treatment (controls, n = 36). Ultrasonography (every 3 months) and computed tomography (every 6 months) were performed to check the portal vein axis. The primary outcome was pre…

medicine.medical_specialtyCirrhosisIntention-to-treat analysisHepatologybusiness.industrycirrhosisGastroenterologyPortal vein trombosis; Enoxaparin; cirrhosisenoxaparin cirrhosis portal thrombosismedicine.diseasePortal vein trombosisSurgeryPortal vein thrombosislaw.inventionSpontaneous bacterial peritonitisModel for End-Stage Liver DiseaseRandomized controlled triallawHepatocellular carcinomaMedicinePortal hypertensionEnoxaparinbusinessGastroenterology
researchProduct

Atherosclerosis, degenerative aortic stenosis and statins

2009

Aortic stenosis is the most common valvular heart disease among adult subjects in western countries The current treatment for aortic stenosis is aortic valve replacement. The possibility of a medical treatment that can slow the progression of aortic stenosis is very fascinating and statins have been tested to reduce the progression of degenerative aortic stenosis (DAS). The rationale for statin treatment in DAS has a deep pathophysiological substrate, in fact inflammation and lipid infiltration constitute the same histopathological pattern of both aortic stenosis and atherosclerosis and these two conditions have the same risk factors. Whether retrospective studies have shown some efficacy o…

medicine.medical_specialtyClinical BiochemistryInflammationlaw.inventionCoronary artery diseaseRandomized controlled trialAortic valve replacementlawInternal medicineDrug DiscoverymedicineAnimalsHumansPharmacologyEvidence-Based Medicinebusiness.industryvalvular heart diseaseRetrospective cohort studyAortic Valve Stenosismedicine.diseaseAtherosclerosisSettore MED/11 - Malattie Dell'Apparato Cardiovascolareatherosclerosis aortic stenosis statinStenosiscardiovascular systemCardiologyMolecular Medicinemedicine.symptomHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessCalcification
researchProduct

The treatment of portal hypertension: a meta-analytic review.

1995

medicine.medical_specialtyClinical Trials as TopicHepatologybusiness.industryVascular diseaseMEDLINEHemorrhageVariceal hemorrhagemedicine.diseaseGastroesophageal variceslaw.inventionSurgeryVaricose VeinsText miningRandomized controlled triallawRecurrenceRisk FactorsMeta-analysisHypertension PortalmedicinePortal hypertensionHumansIntensive care medicinebusinessHepatology (Baltimore, Md.)
researchProduct

The necessity of placebo application in psychotropic drug trials.

1990

medicine.medical_specialtyClinical Trials as TopicPsychotropic DrugsPsychotherapistMEDLINEGeneral MedicinePlaceboClinical trialPlacebosPsychiatry and Mental healthPsychotropic drugmedicineHumansPharmacology (medical)PsychopharmacologyPsychiatryPsychologyDepression (differential diagnoses)Randomized Controlled Trials as TopicPharmacopsychiatry
researchProduct

Randomized Controlled Trials

2011

Background In clinical research, randomized controlled trials (RCTs) are the best way to study the safety and efficacy of new treatments. RCTs are used to answer patient-related questions and are required by governmental regulatory bodies as the basis for approval decisions.

medicine.medical_specialtyClinical researchRandomized controlled trialbusiness.industrylawAlternative medicinemedicineMEDLINEMedical physicsGeneral Medicinebusinesslaw.inventionDeutsches Ärzteblatt international
researchProduct

Feasibility and Safety of Laparoscopic Complete Mesocolic Excision (CME) for Right-sided Colon Cancer

2020

OBJECTIVE The aim of this prospective clinical study is to compare short-term outcome of laparoscopic right hemicolectomy using the Complete Mesocolic Excision (CME group) with patients who underwent conventional right-sided colonic resection (NCME group). SUMMARY BACKGROUND DATA Although CME with central vascular ligation in laparoscopic right hemicolectomy is associated with a significant decrease in local recurrence rates and improvements in cancer-related 5-year survival, there may be additional risks associated with this technique because of increased surgical complications. As a result, there is controversy surrounding its use. METHODS In this randomized controlled trial, several prim…

medicine.medical_specialtyColorectal cancerMEDLINEAnastomosislaw.inventionClinical study03 medical and health sciencesText mining0302 clinical medicineRandomized controlled triallawHumansMedicinelaparoscopic colonic resectionbusiness.industryGeneral surgerymedicine.diseaselaparoscopic surgeryTerm (time)SurgerySettore MED/18 - Chirurgia Generale030220 oncology & carcinogenesisColonic Neoplasmsright colon cancerFeasibility StudiesOperative timeLaparoscopy030211 gastroenterology & hepatologySurgerycomplete mesocolic excisionLymphSpecimen lengthbusinessLigationMesocolonAnnals of Surgery
researchProduct

Current state of dynamic surgery. A literature review.

2021

Background Recently, dental implant technology has been widely used for oral reconstruction. Dental implants are the treatment of choice for those patients with dental absences. An optimal implant placement is based on the prosthetic driven concept in order to achieve an aesthetic and functional restoration with a long-term prognosis. There are two types of guided implant surgery that are described in the literature: Static Guided Surgery (SGS) and Dynamic Guided Surgery (DGS). The aim of this study is to be aware of the current state of dynamic surgery and compare in the literature the discrepancies between planning and placement of dental implants. Material and Methods The study consists …

medicine.medical_specialtyComputer sciencemedicine.medical_treatmentMEDLINEContext (language use)frailtyReviewEsthetics DentalImplant surgerylaw.inventionhead and neck neoplasmsRandomized controlled triallawpostoperative complicationsmedicineHumansDental implantGeneral DentistryUNESCO:CIENCIAS MÉDICASDental ImplantsDental Implantation EndosseousmortalityOral reconstructionSurgeryImplant placementOtorhinolaryngologySurgeryImplantologyMedicina oral, patologia oral y cirugia bucal
researchProduct

Guidelines for time-to-event end point definitions in sarcomas and gastrointestinal stromal tumors (GIST) trials: results of the DATECAN initiative (…

2015

ABSTRACT The DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials) aims to provide recommendations for definitions of time-to-event end points in cancer randomized controlled trials. We relied on a consensus method based on a multidisciplinary panel of experts to develop these guidelines for trials on sarcomas and gastrointestinal stromal tumors. Background The use of potential surrogate end points for overall survival, such as disease-free survival (DFS) or time-to-treatment failure (TTF) is increasingly common in randomized controlled trials (RCTs) in cancer. However, the definition of time-to-event (TTE) end points is rarely precise and lacks unif…

medicine.medical_specialtyConsensusTime FactorssarcomaDelphi TechniqueEndpoint Determination[SDV]Life Sciences [q-bio]Disease-Free Survivallaw.invention03 medical and health sciencesgastrointestinal stromal tumors0302 clinical medicineRandomized controlled trialSDG 3 - Good Health and Well-beinglawMultidisciplinary approachTerminology as TopicmedicineHumansMedical physicsTreatment Failureguidelinestime-to-event end pointComputingMilieux_MISCELLANEOUSRandomized Controlled Trials as Topic030304 developmental biologyEvent (probability theory)0303 health sciencesEnd pointGiSTSurrogate endpointbusiness.industryefficacy measureCancerHematologymedicine.disease3. Good healthOncologyResearch Design030220 oncology & carcinogenesisrandomized controlled trialDisease ProgressionRadiologySarcomabusiness
researchProduct